Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 act mut S-49076 stomach carcinoma sensitive detail...
CDKN2A R80* Palbociclib stomach carcinoma sensitive detail...
FGFR2 amp PRN1371 stomach carcinoma sensitive detail...
FGFR2 amp RO4987655 stomach carcinoma no benefit detail...
FGFR2 amp RO5126766 stomach carcinoma no benefit detail...
FGFR2 amp Debio 1347 stomach carcinoma sensitive detail...
BRAF mutant KO-947 stomach carcinoma predicted - sensitive detail...
NRAS mutant KO-947 stomach carcinoma predicted - sensitive detail...
FGFR2 amp CPL304110 stomach carcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01183559 Phase I Carboplatin + Fluorouracil + Paclitaxel + Vandetanib A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery Completed USA 0
NCT02065765 Phase II Ramucirumab International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer No longer available NLD | DEU | AUT 2
NCT02274012 Phase II Afatinib + Paclitaxel Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer Withdrawn 0
NCT02344810 Phase Ib/II AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Withdrawn USA 0
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Completed USA | NLD | GBR | FRA | ESP | DEU | BEL 4
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ESP 0
NCT02773524 Phase III Regorafenib A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) Unknown status USA | NZL | CAN | AUS 3
NCT02830594 Phase II Pembrolizumab Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Completed USA 0
NCT02892123 Phase I Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers Active, not recruiting USA | CAN 1
NCT03008278 Phase Ib/II Olaparib + Ramucirumab Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Unknown status USA 0
NCT03288350 Phase II Cisplatin + Docetaxel + Fluorouracil Avelumab mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) Unknown status CAN 0
NCT03474640 Phase I Toripalimab-tpzi Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Unknown status USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03957096 Phase I SGN-CD47M A Safety Study of SGN-CD47M in Patients With Solid Tumors Terminated USA 0
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT04047862 Phase I BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors Active, not recruiting USA | AUS 2
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04254107 Phase I SGN-TGT Pembrolizumab + SGN-TGT A Safety Study of SGN-TGT in Patients With Advanced Cancer Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Terminated USA | ITA | FRA | ESP | DEU | CAN 8
NCT04594811 Phase II Nivolumab Nivolumab + NT-I7 NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma Terminated USA 1
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 0
NCT04752215 Phase I BI 765049 + Ezabenlimab BI 765049 A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface Recruiting USA | CAN 0
NCT04879368 Phase III Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Recruiting USA | ITA | ESP | DEU | AUT | AUS 3
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Recruiting USA | GBR 0
NCT05143970 Phase I IPH5301 IPH5301 + Paclitaxel + Trastuzumab A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) Recruiting FRA 0
NCT05163041 Phase Ib/II BT7480 BT7480 + Nivolumab Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression Recruiting USA | GBR 0
NCT05548634 Phase I TAVO412 A Study of TAVO412 in Patients With Cancer (TAVO412) Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT06131840 Phase I SGN-CEACAM5C A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Recruiting USA 0